In the current study, adding adiponectin beyond traditional risk factors and glucose markers (random glucose or HbA1c) did not improve discrimination (assessed by AUC), but improved risk reclassification (assessed by NRI and IDI) for T2D. Here, ADIPOQ is linked to type 2 diabetes mellitus.